alanine has been researched along with Grippe in 10 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The International Society for Influenza and other Respiratory Virus Diseases held its 6th Antiviral Group (isirv-AVG) conference in Rockville, Maryland, November 13-15, 2018." | 2.61 | Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. ( Adams, PL; Beigel, JH; El-Kamary, SS; Ince, WL; Krafft, A; Nam, HH; Sims, AC, 2019) |
| "In mice infected with influenza A virus (IAV) and in patients with severe COVID-19 requiring artificial ventilation or extracorporeal membrane oxygenation, blood levels of d-amino acids, including d-alanine, were reduced significantly compared with those of uninfected mice or healthy controls." | 1.91 | d-Alanine as a biomarker and a therapeutic option for severe influenza virus infection and COVID-19. ( Asaka, MN; Isaka, Y; Kimura, T; Kimura-Ohba, S; Takabatake, Y; Takahashi, A; Utsumi, D; Yasutomi, Y, 2023) |
| "The nucleoprotein (NP) of influenza A virus is transported into the nucleus via the classical importin α/β pathway, and proceeds via nuclear localization signals (NLSs) recognized by importin α molecules." | 1.39 | Importin α3/Qip1 is involved in multiplication of mutant influenza virus with alanine mutation at amino acid 9 independently of nuclear transport function. ( Aida, Y; Hagiwara, K; Kakisaka, M; Murakami, T; Sasaki, Y; Yamada, K, 2013) |
| "A mutant influenza A virus expressing the L69,77A NS1 protein was generated using reverse genetics." | 1.37 | Alanine substitutions within a linker region of the influenza A virus non-structural protein 1 alter its subcellular localization and attenuate virus replication. ( Li, W; Noah, DL; Noah, JW, 2011) |
| "The interest in broad-range anti-influenza A monoclonal antibodies (mAbs) has recently been strengthened by the identification of anti-hemagglutinin (HA) mAbs endowed with heterosubtypic neutralizing activity to be used in the design of "universal" prophylactic or therapeutic tools." | 1.37 | A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. ( Burioni, R; Clementi, M; Clementi, N; De Marco, D; Di Pietro, A; Gubareva, LV; Mancini, N; Mishin, V; Moreno, GJ; Siccardi, AG; Solforosi, L; Vicenzi, E, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kimura-Ohba, S | 1 |
| Asaka, MN | 1 |
| Utsumi, D | 1 |
| Takabatake, Y | 1 |
| Takahashi, A | 1 |
| Yasutomi, Y | 1 |
| Isaka, Y | 1 |
| Kimura, T | 1 |
| Li, G | 1 |
| De Clercq, E | 1 |
| Anderson, PO | 1 |
| Milano, G | 1 |
| Dolgin, E | 1 |
| Beigel, JH | 1 |
| Nam, HH | 1 |
| Adams, PL | 1 |
| Krafft, A | 1 |
| Ince, WL | 1 |
| El-Kamary, SS | 1 |
| Sims, AC | 1 |
| Knight, CA | 1 |
| Li, W | 1 |
| Noah, JW | 1 |
| Noah, DL | 1 |
| Clementi, N | 1 |
| De Marco, D | 1 |
| Mancini, N | 1 |
| Solforosi, L | 1 |
| Moreno, GJ | 1 |
| Gubareva, LV | 1 |
| Mishin, V | 1 |
| Di Pietro, A | 1 |
| Vicenzi, E | 1 |
| Siccardi, AG | 1 |
| Clementi, M | 1 |
| Burioni, R | 1 |
| Sasaki, Y | 1 |
| Hagiwara, K | 1 |
| Kakisaka, M | 1 |
| Yamada, K | 1 |
| Murakami, T | 1 |
| Aida, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist[NCT04594356] | 120 participants (Actual) | Observational | 2020-11-19 | Completed | |||
| Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection[NCT04326036] | Early Phase 1 | 10 participants (Anticipated) | Interventional | 2020-03-25 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for alanine and Grippe
| Article | Year |
|---|---|
Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Coronavirus Infections; Humans; Influenza, Human | 2019 |
9 other studies available for alanine and Grippe
| Article | Year |
|---|---|
d-Alanine as a biomarker and a therapeutic option for severe influenza virus infection and COVID-19.
Topics: Alanine; Animals; Biomarkers; Communicable Diseases; COVID-19 Drug Treatment; Humans; Influenza, Hum | 2023 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Breastfeeding and Respiratory Antivirals: Coronavirus and Influenza.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Breast Feeding; Coronavirus Inf | 2020 |
[Scientific research in times of pandemics.]
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19; COVID-19 Vaccines; Disease Outbreaks; | 2021 |
The race for antiviral drugs to beat COVID - and the next pandemic.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Birds; Clinical Trials as Topic; Corona | 2021 |
AMINO ACID COMPOSITION OF HIGHLY PURIFIED VIRAL PARTICLES OF INFLUENZA A AND B.
Topics: Alanine; Amino Acids; Arginine; Aspartic Acid; Glutamates; Glycine; Histidine; Humans; Influenza, Hu | 1947 |
Alanine substitutions within a linker region of the influenza A virus non-structural protein 1 alter its subcellular localization and attenuate virus replication.
Topics: Alanine; Amino Acid Motifs; Amino Acid Substitution; Animals; Cell Line; Dogs; Humans; Influenza A v | 2011 |
A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes.
Topics: Alanine; Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Cell Line; Cluster Analysis; Dog | 2011 |
Importin α3/Qip1 is involved in multiplication of mutant influenza virus with alanine mutation at amino acid 9 independently of nuclear transport function.
Topics: Active Transport, Cell Nucleus; Alanine; alpha Karyopherins; Amino Acid Sequence; Animals; Cell Line | 2013 |